 - NSCLC patients may be entered after a minimum of 4-6 cycles of first line combination chemotherapy; if the patient is 70 years a single agent regimen is acceptable. If the patient has documented EGFR or ALK mutations, treatment they may have received may include an EGFR inhibitor or ALK inhibitor as first line therapy. 